CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $0, lower than 95% of all stocks globally
- PositionCurrent ratio is 28.05×, higher than 95% of its Biotechnology peers (median 5.64×)
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
745.89MUSDvs all stocks (USD)
Revenue (TTM)
0.00USDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
-0.5110xvs all stocks
52-Week Change
54.95%vs all stocks
Market Capitalization
745.89MUSDvs all stocks (USD)
Enterprise Value
549.04MUSDvs all stocks (USD)
Forward P/E
-15.67xvs Biotechnology peers
Price to Book (MRQ)
5.03xvs Biotechnology peers
Enterprise to EBITDA
-9.88xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-23.64%vs Biotechnology peers
Return on Equity (TTM)
-51.17%vs Biotechnology peers
Revenue (TTM)
0.00USDvs all stocks (USD)
Revenue per Share (TTM)
0.00USDUpdated Jul 18, 2026Gross Profit (TTM)
0.00USDvs all stocks (USD)
EBITDA (TTM)
-55.58MUSDvs all stocks (USD)
Net Income (TTM)
-54.42MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-47.73MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-37.90MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 18, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
0.00USDFY2025 · Dec 31, 2025Operating Income
-48.18MUSDvs all stocks (USD)
Pre-tax Income
-38.18MUSDFY2025 · Dec 31, 2025Net Income
-38.18MUSDFY2025 · Dec 31, 2025EBIT
-36.06MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-43.42MUSDFY2025 · Dec 31, 2025Research & Development
30.50MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
17.77MUSDFY2025 · Dec 31, 2025Other Operating Expenses
-89.00KUSDFY2025 · Dec 31, 2025Non-operating Interest Income
3.92MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
2.12MUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-38.18MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-32.25MUSDFY2025 · Dec 31, 2025Free Cash Flow
-32.81MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
120.15MUSDFY2025 · Dec 31, 2025Interest Paid
1.28MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-38.18MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
845.00KUSDFY2025 · Dec 31, 2025Stock-based Compensation
3.82MUSDFY2025 · Dec 31, 2025Other Non-cash Items
819.00KUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
802.00KUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-355.00KUSDFY2025 · Dec 31, 2025Capital Expenditures
-560.00KUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-560.00KUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
47.95MUSDFY2025 · Dec 31, 2025Long-term Debt Payments
-11.73MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
55.58MUSDFY2025 · Dec 31, 2025Shares Outstanding
73.26MSharesUpdated Jul 18, 2026Float Shares
56.81MSharesUpdated Jul 18, 2026Shares Short
16.14MSharesUpdated Jul 18, 2026Short Ratio
7.19daysvs all stocks
Short % of Shares Outstanding
28.68%vs all stocks
% Held by Insiders
15.53%vs all stocks
% Held by Institutions
60.02%vs all stocks
Total Cash (MRQ)
194.83MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
2.66USDUpdated Jul 18, 2026Total Debt (MRQ)
49.27MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.3570xvs Biotechnology peers
Current Ratio (MRQ)
28.05xvs Biotechnology peers
Book Value per Share (MRQ)
1.88USDUpdated Jul 18, 2026Total Assets
125.19MUSDvs all stocks (USD)
Total Current Assets
121.39MUSDFY2025 · Dec 31, 2025Total Liabilities
73.27MUSDFY2025 · Dec 31, 2025Total Non-current Assets
3.81MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
64.28MUSDFY2025 · Dec 31, 2025Total Current Liabilities
9.00MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
119.73MUSDFY2025 · Dec 31, 2025Accounts Payable
1.13MUSDFY2025 · Dec 31, 2025Short-term Debt
445.00KUSDFY2025 · Dec 31, 2025Other Current Liabilities
89.00KUSDFY2025 · Dec 31, 2025Long-term Debt
48.59MUSDFY2025 · Dec 31, 2025Common Stock (Book)
550.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-230.39MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
51.92MUSDvs all stocks (USD)
Treasury Stock
448.00KUSDFY2025 · Dec 31, 202552-Week Low
4.35USDUpdated Jul 18, 202652-Week High
11.36USDUpdated Jul 18, 202652-Week Change
54.95%vs all stocks
Beta
-0.5110xvs all stocks
50-Day MA
8.81USDUpdated Jul 18, 2026200-Day MA
6.31USDUpdated Jul 18, 2026Avg 10-Day Volume
1.36MSharesUpdated Jul 18, 2026Avg 30-Day Volume
1.98MSharesUpdated Jul 18, 2026Diluted EPS (TTM)
-0.9900USDUpdated Jul 18, 2026Other Income / Expense
8.20MUSDFY2025 · Dec 31, 20251 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Cash Elevated Relative to Current Liabilities and Total Assets
Its cash covers more of its near-term bills than in its industry, and is a large share of everything it owns.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Current ratio is 28.05×, higher than 95% of its Biotechnology peers (median 5.64×)Significant
Current ratio: 28.05Industry median: 5.64Industry P95: 23.02Peers compared: 261
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -0.81
Altman Z-Score 3.66: safe zoneNotable
Altman Z-Score: 3.66
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $0, lower than 95% of all stocks globallySignificant
Revenue (USD): 0.00Global P5: 30,274,777.221
Companies that share the same coordination system — how they create, deliver, or capture value.
Bright Minds Biosciences Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Monopar Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Neurogene Inc.
Tier 1ProductionApproval-Gated PipelineRule
Aclaris Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Rigel Pharmaceuticals, Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Jiangsu Lianhuan Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Zhuzhou Qianjin Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Zevra Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai Sanyou Medical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Oculis Holding AG
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Aeva Technologies, Inc.
1 interpretationCash Elevated Relative to Current Liabilities and Total Assets
Immunome Inc.
1 interpretationCash Elevated Relative to Current Liabilities and Total Assets
Inhibikase Therapeutics Inc.
1 interpretationCash Elevated Relative to Current Liabilities and Total Assets